Mohit Narang, MD

Concurrent chemoradiotherapy remains curative-intent therapy for limited-stage disease, yet cure rates without immunotherapy stall near thirty percent, a ceiling that scheduling choices and careful monitoring can only partly raise on their own.

Small cell lung cancer's stark divide between curable, localized disease and systemic, incurable disease shapes every treatment decision that follows, and screening gains are slowly shifting how many patients get caught early enough to benefit.

Mohit Narang, MD, discusses how community oncology practices can expand access to CAR T and bispecific therapies through better infrastructure and collaboration.

Switching patients with chronic lymphocytic leukemia (CLL) from ibrutinib to zanubrutinib has led to fewer cardiac adverse effects and a reduced workload for Mohit Narang, MD, managing partner at Maryland Oncology Hematology.

Mohit Narang, MD, explains why he switches patients with chronic lymphocytic leukemia (CLL) to the second-generation Bruton tyrosine kinase inhibitor.